Holen Sie sich die Stockscreener-App
0.3055
2.86%
0.0085
Handel nachbörslich:
.29
-0.0155
-5.07%
Schlusskurs vom Vortag:
$0.297
Offen:
$0.3
24-Stunden-Volumen:
559.39K
Relative Volume:
0.02
Marktkapitalisierung:
$8.47M
Einnahmen:
$94,000
Nettoeinkommen (Verlust:
$-13.28M
KGV:
-0.0419
EPS:
-7.2965
Netto-Cashflow:
$-11.67M
1W Leistung:
+7.57%
1M Leistung:
-40.77%
6M Leistung:
-76.29%
1J Leistung:
-96.54%
1-Tages-Spanne:
$0.285
$0.3055
1-Wochen-Bereich:
$0.279
$0.3083
52-Wochen-Spanne:
$0.21
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.3055 | 8.23M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech spotlights pancreatic cancer program progress in CEO video - Stock Titan
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM ImmunoTech(AIM) Stock Options Chain | Quotes & News - Moomoo
AIMAIM ImmunoTech Inc Latest SEC Filings - Finviz
AIM Should I Buy - Intellectia AI
Price to sales forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Enterprise value to EBIT forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to EBITDA forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to EBITDA forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Enterprise value to revenue forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to revenue forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Price to earnings forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
AIM ImmunoTech Inc. Actuals & Estimates (FWB:HXB) - TradingView
AIM ImmunoTech Inc. Actuals & Estimates (AMEX:AIM) - TradingView
AIM Forecast — Price Target — Prediction for 2027 - TradingView
AIM ImmunoTech (NYSE: AIM) seeks approval for major warrant financings and up to 1-for-25 reverse split - Stock Titan
AIM ImmunoTech (AIM) registers 13.08M shares for resale after June Offering - Stock Titan
AIM ImmunoTech Company Profile & Introduction - Moomoo
AIM ImmunoTech outlines pancreatic cancer trial milestones By Investing.com - Investing.com South Africa
AIM ImmunoTech outlines pancreatic cancer trial milestones - Investing.com
AIM ImmunoTech Accelerates Toward Potential Pivotal - GlobeNewswire
AIM ImmunoTech’s pancreatic cancer study hits a key milestone - Stock Titan
[EFFECT] AIM ImmunoTech Inc. SEC Filing - Stock Titan
AIM ImmunoTech Q1 2026 Earnings: Wider-Than-Expected Loss as Company Continues Clinical ProgressManagement Tone Analysis - dars.gov.et
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - The Manila Times
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech (NYSE American: AIM) resale of 31.3M warrant‑related shares - Stock Titan
AIM ImmunoTech (AIM) News, Articles, Events & Latest Updates - Stocktwits
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - The Manila Times
Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders - TradingView
AIM ImmunoTech clears final dose milestone in pancreatic cancer trial - Stock Titan
AIM ImmunoTech Achieves Clinical Milestone as Final Subject - GlobeNewswire
AIM ImmunoTech (NYSE: AIM) registers 13.1M shares for resale in June deals - Stock Titan
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AIM ImmunoTechFiles to Offer and Resell up - Moomoo
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AIM ImmunoTech Inc (AIM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AIM ImmunoTech Inc (AIM) Valuation: PE, PB & Fair Value Analysis - TradingKey
AIM ImmunoTech Regains NYSE American Listing Compliance - The Globe and Mail
AIM ImmunoTech (AIM) seeks approvals to issue >19.99% shares, reverse split option - Stock Titan
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - The Manila Times
AIM Regains NYSE American Compliance After Equity-Boosting Financings - TradingView
AIM ImmunoTech (NYSE: AIM) lifts equity, regains NYSE American listing standards - Stock Titan
NYSE lifts compliance tag on AIM ImmunoTech after new equity financings - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million At-Market Financing to Advance Clinical Trials and Drug Development 1 - Minichart
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):